Dan L Duncan Comprehensive Cancer Center to open cell therapy clinical trials at Harris Health

City of Hope Atlanta opens Blood and Marrow Transplantation and Cell Therapy Program

City of Hope has opened a Blood and Marrow Transplantation and Cell Therapy Program at City of Hope Cancer Center Atlanta.

March 29, 2024

Vol.50 No.13

In Brief

A. Samer Al-Homsi named system chief of blood and marrow transplant and cellular therapy at Northwell

A. Samer Al-Homsi, a leader in hematology, was appointed as system chief of blood and marrow transplant and cellular therapy at the Northwell Health Cancer Institute.

March 29, 2024

Vol.50 No.13

Clinical

First-ever commercial TIL therapy: How NCI, Iovance, and Moffitt achieved FDA approval

In a major breakthrough in cellular therapy, FDA has approved the first tumor-infiltrating lymphocyte therapy for patients with unresectable or metastatic melanoma who have received prior treatment, including with checkpoint inhibitors.

February 23, 2024

Vol.50 No.08

By Matthew Bin Han Ong

Conversation with The Cancer Letter

Steven Rosenberg, Friedrich Graf Finckenstein: FDA recognition of TIL therapy is the result of 40 years of research

Feb. 16, 2024, is a landmark date in the history of immuno-oncology.

February 23, 2024

Vol.50 No.08

By Matthew Bin Han Ong

In Brief

Damian Green named chief of Division of Transplantation & Cellular Therapy at Sylvester

Damian Green will join Sylvester Comprehensive Cancer Center at the University Miami Miller School of Medicine this spring to lead its transplantation and cellular therapy services. Green was named chief of the Division of Transplantation & Cellular Therapy, as well as assistant director of Translational Research, beginning March 1.

February 23, 2024

Vol.50 No.08

Regulatory News

FDA tells sponsors of CAR T-cell therapies to add boxed warning about secondary T-cell malignancies

FDA has directed the sponsors of CAR T-cell therapies to place boxed warnings on their products to indicate that the agents may cause secondary T-cell malignancies.

February 02, 2024

Vol.50 No.05

By Alexandria Carolan

Dan L Duncan Comprehensive Cancer Center to open cell therapy clinical trials at Harris Health

YOU MAY BE INTERESTED IN

City of Hope Atlanta opens Blood and Marrow Transplantation and Cell Therapy Program

A. Samer Al-Homsi named system chief of blood and marrow transplant and cellular therapy at Northwell

First-ever commercial TIL therapy: How NCI, Iovance, and Moffitt achieved FDA approval

Steven Rosenberg, Friedrich Graf Finckenstein: FDA recognition of TIL therapy is the result of 40 years of research

Damian Green named chief of Division of Transplantation & Cellular Therapy at Sylvester

FDA tells sponsors of CAR T-cell therapies to add boxed warning about secondary T-cell malignancies

Renew today!

Subscriber content

Login